alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>

                                  [LETTERHEAD]




                 Consent of George A. Hieronymus and Company, L.L.C.
                                           

We consent to the incorporation by reference in this Amended Annual Report on 
Form 10-K/A, filed with the Securities and Exchange Commission by NHP 
Incorporated (NHP) of our reports dated as shown in Exhibit A with respect to 
the audit of those entities as shown in Exhibit A for the year ended December 
31, 1994, and the incorporation by reference of such report into NHP's 
Registration Statement on Form S-8 (No. 333-11933), NHP's Registration 
Statement on Form S-8 (No. 333-11863), NHP's Registration Statement of Form 
S-8 (333-11917), NHP's Registration Statement on Form S-8 (333-11857), and 
NHP's Registration Statement on Form S-8 (333-08137).



   
/s/ George A. Hieronymus and Company L.L.C.
--------------------------------------------
George A. Hieronymus and Company, L.L.C.
Mobile, Alabama
October 27, 1997
    




<PAGE>

                                E X H I B I T   A



<TABLE>
<CAPTION>
<S>                                                       <C>
Real Estate Partnership                                   Report Date
-----------------------                                   -----------

Athens Arms Associates                                    January 27, 1995

Colonial Terrace I Associates                             January 27, 1995

Colonial Terrace II Associates                            January 27, 1995


</TABLE>
<PAGE>   1

EXHIBIT 10.6               FOURTH AMENDMENT AGREEMENT

THIS AGREEMENT is dated for reference the 1st day of March, 1999

AMONG:

                ACCEL FINANCIAL GROUP LTD., a corporation incorporated under the
                laws of Alberta

                (the "Corporation")

AND:

                802685 ALBERTA LTD., a corporation incorporated under the laws
                of Alberta

                ("Holdco")

AND:

                T&W FINANCIAL SERVICES COMPANY L.L.C., a limited liability
                company incorporated under the laws of the State of Washington

                ("T&W")

WHEREAS:

(A)     The parties hereto are parties to an amalgamation agreement dated
November 6, 1998, as amended by an amendment agreement dated December 7, 1998, a
second amendment agreement dated January 19, 1999 and third amendment agreement
dated February 12, 1999 (collectively, the "Amalgamation Agreement");

(B)     The parties wish to enter into this Agreement to amend the Amalgamation
Agreement in order to make effective certain amendments that they have agreed
to.

THEREFORE THIS AGREEMENT WITNESSES that the parties agree as follows:

1.      The Amalgamation Agreement is hereby amended by deleting the existing
definition of "Effective Date" in Section 1 and replacing it with the following
provision:

        "Effective Date" means the date shown on the certificate of amalgamation
        to be issued in respect of the Amalgamation which will be March 15, 1999
        or such earlier date on which all conditions precedent to the
        Amalgamation have been satisfied or waived;"


<PAGE>   2
                                     - 2 -


2.      The amendments described in Section 1 above, will have the same force
and effect as if originally contained in the Amalgamation Agreement.

3.      In all other respects the terms and conditions of the Amalgamation
Agreement are hereby confirmed as being in full force and effect.


IN WITNESS WHEREOF the parties have caused this agreement to be executed as of
the _________ day of March, 1999.

ACCEL FINANCIAL GROUP LTD.

By: BJ Buan
   ----------------------------------
    Name

802685 ALBERTA LTD.

By: Paul B. Luke
   ----------------------------------
    Name

T&W FINANCIAL SERVICES COMPANY, L.L.C.

By: Paul B. Luke
   ----------------------------------
   Name
[Federal Register Volume 75, Number 34 (Monday, February 22, 2010)]
[Notices]
[Page 7649]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3412]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF STATE

[PUBLIC NOTICE 6901]


Culturally Significant Objects Imported for Exhibition 
Determinations: ``Otto Dix''

SUMMARY: Notice is hereby given of the following determinations: 
Pursuant to the authority vested in me by the Act of October 19, 1965 
(79 Stat. 985; 22 U.S.C. 2459), Executive Order 12047 of March 27, 
1978, the Foreign Affairs Reform and Restructuring Act of 1998 (112 
Stat. 2681, et seq.; 22 U.S.C. 6501 note, et seq.), Delegation of 
Authority No. 234 of October 1, 1999, Delegation of Authority No. 236 
of October 19, 1999, as amended, and Delegation of Authority No. 257 of 
April 15, 2003 [68 FR 19875], I hereby determine that the objects to be 
included in the exhibition ``Otto Dix,'' imported from abroad for 
temporary exhibition within the United States, are of cultural 
significance. The objects are imported pursuant to loan agreements with 
the foreign owners or custodians. I also determine that the exhibition 
or display of the exhibit objects at the Neue Galerie, New York, New 
York, from on or about March 11, 2010, until on or about August 10, 
2010, and at possible additional exhibitions or venues yet to be 
determined, is in the national interest. I have ordered that Public 
Notice of these Determinations be published in the Federal Register.

FOR FURTHER INFORMATION CONTACT: For further information, including a 
list of the exhibit objects, contact Paul W. Manning, Attorney-Adviser, 
Office of the Legal Adviser, U.S. Department of State (telephone: 202-
632-6469). The mailing address is U.S. Department of State, SA-5, L/PD, 
Fifth Floor (Suite 5H03), Washington, DC 20522-0505.

    Dated: February 17, 2010.
Maura M. Pally,
Deputy Assistant Secretary for Professional and Cultural Exchanges, 
Bureau of Educational and Cultural Affairs, Department of State.
[FR Doc. 2010-3412 Filed 2-19-10; 8:45 am]
BILLING CODE 4710-05-P
###### Editorial Note on Part 137

#### Editorial Note:

Nomenclature changes to part 137 appear at 63 FR 14035, Mar. 24, 1998.

#### § 137.155 Bromated flour.

Bromated flour conforms to the definition and standard of identity, and is subject to the requirements for label statement of ingredients, prescribed for flour by § 137.105, except that potassium bromate is added in a quantity not exceeding 50 parts to each million parts of the finished bromated flour, and is added only to flours whose baking qualities are improved by such addition.

[57 FR 2877, Jan. 6, 1993]
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 729 Introduced in House (IH)]

<DOC>

118th CONGRESS
  1st Session
                                H. R. 729

  To require the Secretary of the Interior to remove the Emancipation 
 Memorial from Lincoln Park in the District of Columbia, and for other 
                               purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            February 1, 2023

   Ms. Norton (for herself, Mr. Huffman, Ms. Clarke of New York, Mr. 
    Blumenauer, Mr. Green of Texas, Mr. McGovern, and Mr. Grijalva) 
 introduced the following bill; which was referred to the Committee on 
                           Natural Resources

_______________________________________________________________________

                                 A BILL

 
  To require the Secretary of the Interior to remove the Emancipation 
 Memorial from Lincoln Park in the District of Columbia, and for other 
                               purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Emancipation Statue Removal Act''.

SEC. 2. REMOVAL OF EMANCIPATION MEMORIAL.

    (a) Removal.--The Secretary of the Interior shall remove the 
Emancipation Memorial from Lincoln Park in the District of Columbia.
    (b) Donation.--The Secretary shall donate the Emancipation Memorial 
to a museum or other similar entity. The recipient of the Emancipation 
Memorial may not store, display, or exhibit the Emancipation Memorial 
outside. If the Emancipation Memorial is stored, displayed, or 
exhibited outside, ownership of the Emancipation Memorial will revert 
back to the Federal Government.
                                 <all>
```
**Exhibit32**

 

**CERTIFICATIONPURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

In connection with the Quarterly Report of Pace Medical, Inc. (the“Company”) on Form 10-QSB for the period ending March 31, 2004 as filedwith the Securities and Exchange Commission on the date hereof (the “Report”),I, Ralph E. Hanson, President and Treasurer of the Company, being the chiefexecutive officer and the chief financial officer of the Company, certify,pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of theSarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements ofsection 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in allmaterial respects, the financial condition and results of operations of theCompany.

 

 
| /s/ Ralph E. Hanson     |   |
|-------------------------|--------|
| Ralph E. Hanson         |
| President and Treasurer |
|                    |
| May 24, 2004            |

 

----
§ 507.69 Procedure for submitting an appeal. ( a ) To appeal an order to withdraw a qualified facility exemption, you must: ( 1 ) Submit the appeal in writing to the FDA Division Director in whose division the facility is located (or, in the case of a foreign facility, the Director of the Division of Compliance in the Center for Veterinary Medicine), at the mailing address, email address, or fax number identified in the order within 15 calendar days of the date of receipt of confirmation of the order; and
( 2 ) Respond with particularity to the facts and issues contained in the order, including any supporting documentation upon which you rely.
( b ) In a written appeal of the order withdrawing an exemption provided under § 507.5(d), you may include a written request for an informal hearing as provided in § 507.71.
[80 FR 56337, Sept. 17, 2015, as amended at 81 FR 3718, Jan. 22, 2016; 85 FR 16554, Mar. 24, 2020]
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Child Health and Human Development Special Emphasis Panel, Population Research Infrastructure Program.                    

*Date:*                         March 24, 2010.                    

*Time:*                         8 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road, NW., Washington, DC 20015.                    

*Contact Person:*                         Carla T. Walls, PhD, Scientific Review Officer, Division of Scientific Review, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5B01, Bethesda, MD 20892, (301) 435-6898,                         *wallsc@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: February 19, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-3933 Filed 2-25-10; 8:45 am]

BILLING CODE 4140-01-P
§ 3.8 Letter of designation. ( a ) Each request for designation will be reviewed for completeness within 5 working days of receipt. Any request for designation determined to be incomplete will be returned to the applicant with a request for the missing information. The sponsor of an accepted request for designation will be notified of the filing date.
( b ) Within 60 days of the filing date of a request for designation, the product jurisdiction officer will issue a letter of designation to the sponsor, with copies to the centers, specifying the agency component designated to have primary jurisdiction for the premarket review and regulation of the product at issue, and any consulting agency components. The product jurisdiction officer may request a meeting with the sponsor during the review period to discuss the request for designation. If the product jurisdiction officer has not issued a letter of designation within 60 days of the filing date of a request for designation, the sponsor's recommendation of the center with primary jurisdiction, in accordance with § 3.7(c)(3), shall become the designated agency component.
( c ) Request for reconsideration by sponsor: If the sponsor disagrees with the designation, it may request the product jurisdiction officer to reconsider the decision by filing, within 15 days of receipt of the letter of designation, a written request for reconsideration not exceeding 5 pages. No new information may be included in a request for reconsideration. The product jurisdiction officer shall review and act on the request in writing within 15 days of its receipt.
# L_2019118DE.01001001.xml

| 6.5.2019 | DE | Amtsblatt der Europäischen Union | L 118/10 |
| --- | --- | --- | --- |

6.5.2019

DE

Amtsblatt der Europäischen Union

L 118/10

---

Berichtigung der Durchführungsverordnung (EU) 2018/2066 der Kommission vom 19. Dezember 2018 über die Überwachung von und die Berichterstattung über Treibhausgasemissionen gemäß der Richtlinie 2003/87/EG des Europäischen Parlaments und des Rates und zur Änderung der Verordnung (EU) Nr. 601/2012 der Kommission

(
  Amtsblatt der Europäischen Union L 334 vom 31. Dezember 2018
  )

Seite 7, Artikel 3 Nummer 50:

Anstatt:

„50.   ‚Flughafen‘: ein Flughafen im Sinne von Abschnitt 1 Nummer 2 des Anhangs der Entscheidung 2009/450/EG;“

muss es heißen:

„50.   ‚Flugplatz‘: ein Flugplatz im Sinne von Abschnitt 1 Nummer 2 des Anhangs der Entscheidung 2009/450/EG;“.

---
| 1.   | I      have reviewed this Amendment No. 1 to the Annual Report on Form 10-K of      Hospitality Properties Trust; and |
|----------------|-----------------------------------------------------------------------------------------------------------------------|

| 2.   | Based      on my knowledge, this report does not contain any untrue statement of a      material fact or omit to state a material fact necessary to make the      statements made, in light of the circumstances under which such statements      were made, not misleading with respect to the period covered by this      report. |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Date:  April      17, 2009 |   |   | /s/      John G. Murray          |
|--------------------------------------|--------|--------|-------------------------------------------------------------------------------|
|                                 |   |   | John      G. Murray                                                           |
|                                 |   |   | President      and Chief Operating Officer                                    |

----
§ 207.17 Who must register? ( a ) Unless exempt under section 510(g) of the Federal Food, Drug, and Cosmetic Act or this part, all manufacturers, repackers, relabelers, and salvagers must register each domestic establishment that manufactures, repacks, relabels, or salvages a drug, or an animal feed bearing or containing a new animal drug, and each foreign establishment that manufactures, repacks, relabels, or salvages a drug, or an animal feed bearing or containing a new animal drug, that is imported or offered for import into the United States. When operations are conducted at more than one establishment and common ownership and control among all the establishments exists, the parent, subsidiary, or affiliate company may submit registration information for all establishments.
( b ) Private label distributors who do not also manufacture, repack, relabel, or salvage drugs are not required to register under this part. FDA will accept registration or listing information submitted by a private label distributor only if it is acting as an authorized agent for and submitting information that pertains to an establishment that manufactures, repacks, relabels, or salvages drugs.
1 In The 

### Court of Appeals Ninth District of Texas at Beaumont

__________________ N O . 09
- 21
- 00103
- CV

__________________ IN THE INTEREST OF Z.P. AND L.P.

__________________________________________________________________ On Appeal from the 418th District Court Montgomery County, Texas Trial Cause No. 10
- 09
- 10212
- CV

__________________________________________________________________ MEMORANDUM OPINION R.L.P., the father of Z.P. and L.P., appeal ed from the final order in a proceeding filed by his former spouse that modified a prior order

— the order establishing the rights of joint custody between R.L.P. and the mother of Z.P

. and L.P. After R.L.P . filed his appeal, the Clerk of the Ninth Court of Appeals sent him notices to explain he needed to establish indigence to proceed in the appeal without paying the required filing fee . But R.L.P. failed to respond to the letters, and R.L.P. never filed ev idence to support any allegations claim ing indigence . And R.L.P. did not respond to the letters by paying a filing fee in his appeal

. See Tex. R. App. P. 5,
20.1. Finally, R.L.P. has neither arranged to pay the appellate filing fee or arranged2 to pay the f ee proposed by the District Clerk to secure a clerk’s record to support his appeal. See Tex. R. App. P. 37.3(b).
On June 16 , 2021, the Clerk of the Ninth Court of Appeals notified the parties the Court would dismis s the appeal unless R.L.P. paid the required filing fee. I n response to the notice, R.L.P. failed to file any response. In the absence of satisfactory explanation s justifying R.L.P.’s failure to pay the filing fee for his appeal and his failure to arrange to pay for a clerk’s record to support his appeal, we dismiss the appeal for want of prosecution. See Tex. R. App. P. 37.3(b), 42.3.
APPEAL DISMI S SED.
PER CURIAM

Submitted on August 25, 2021 Opinion Delivered August 26, 2021 Before Golemon , C.J., Kreger and Horton, JJ.
### Reported Emissions and Product Content Dyneon/3M 2011 0 0 0 0 No Telomer ProductionDyneon/3M 2011 0 0 0 Production 0

**~··11**

### Reported PercentReductions in Emissions and Product Content Table 3. Reported Percent Reductions in Emissions and ProductContent ofPFOA, Precursors, and HigherHomologues from 

## u.s.

Dyneon/3M 2011 100% No Telomer Production



### ... --111rrTable 4. Reported PercentReductions in Emissions and ProductContentofPFOA, Precursors, and HigherHomologues from Non U.S.

**Oru•r••ti''"~**

Dyneon/3M 2011

-·ir 100% 100% No Telomer Production



### ·-
**-~1111T**3M Fluoropolymers Accomplishments Table Company Reductions Facilities Emissio Product Content f 

# u.s. 100% 100% Non-U.S. 100% 100%

Global 100% 100% I Please enter a%number for each ofthe fields in the table below. When necessary, please combine PFOA, precursors, and higher homologues into one PFOA-equivalent number. In addition, please combine U.S. and non-U.S. reductions into a global reduction, ifpossible
§ 225.65 Equipment cleanout procedures. ( a ) Adequate cleanout procedures for all equipment used in the manufacture and distribution of medicated feeds are essential to maintain proper drug potency and avoid unsafe contamination of feeds with drugs. Such procedures may consist of cleaning by physical means, e.g., vacuuming, sweeping, washing, etc. Alternatively, flushing or sequencing or other equally effective techniques may be used whereby the equipment is cleaned either through use of a feed containing the same drug(s) or through use of drug free feedstuffs.
( b ) All equipment, including that used for storage, processing, mixing, conveying, and distribution that comes in contact with the active drug component, feeds in process, or finished medicated feed shall be subject to all reasonable and effective procedures to prevent unsafe contamination of manufactured feed. The steps used to prevent unsafe contamination of feeds shall include one or more of the following, or other equally effective procedures: ( 1 ) Such procedures shall, where appropriate, consist of physical means (vacuuming, sweeping, or washing), flushing, and/or sequential production of feeds.
( 2 ) If flushing is utilized, the flush material shall be properly identified, stored, and used in a manner to prevent unsafe contamination of other feeds.
( 3 ) If sequential production of medicated feeds is utilized, it shall be on a predetermined basis designed to prevent unsafe contamination of feeds with residual drugs.